<DOC>
	<DOCNO>NCT00196898</DOCNO>
	<brief_summary>Fibrotic valvular heart diseases know rare complication long-time therapy Parkinson 's disease ergot-derivatives include ergot-dopamine agonist . The aim study assess incidence valvular heart disease , may ergot-drug agonist side-effect overall complication dopamine agonist . Incidence , prevalence addiction dose intake duration know far . The reversibility change unknown . To answer question present study design cross sectional study follow 2 year follow-up prospective cohort study .</brief_summary>
	<brief_title>Multicenter Study Fibrotic Valvular Heart Disease Patients With Parkinson 's Disease Treated With Dopamine Agonists</brief_title>
	<detailed_description>Rare incidence pleuropulmonary retroperitoneal fibrosis know complication long-time therapy Parkinson 's disease ( PD ) ergot-drug derivative include ergot dopamine agonist . Particularly appearance fibrotic valvular heart disease Parkinson patient Pergolide therapy cause intense discussion safety dopamine agonist . Single case report similar heart valve change therapy Bromocriptin probably Cabergoline point effect whole substance class ergot-dopamine agonist . Cross-Sectional Study ( part I ) : Within study initial cross-sectional analysis prevalence fibrotic heart valvular disease do . Patients Parkinson 's disease different exposition status recruit . An transthoracal echocardiographic examination ( TTE ) heart perform . Exposition status : - patient ergot-derived dopamine agonist - patient non-ergot-derived dopamine agonist - After TTE-report study population divide affected ( = pathological TTE-report : fibrotic valvular heart disease ) healthy person ( = non-pathological TTE-report : fibrotic valvular heart disease ) . The therapy dopamine agonist stop patient pathological TTE-report . Instead patient treat equivalent dose L-Dopa without COMT-inhibitors . The exist therapy regime remain patient without pathological finding . Longitudinal Section ( part II III ) : The cross-sectional study ( part I ) follow two year follow-up study . Cohort I : - patient pathological TTE-report : fibrotic valvular heart disease - patient without pathological TTE-report : fibrotic valvular heart disease Part II : Within cohort I reversibility fibrotic valvular heart disease analyse regard previously take cumulative dose dopamine agonist . Part III : Within cohort II prospective analysis ( cumulative ) incidence fibrotic valvular heart disease PD patient different exposition status . If fibrotic valvular heart disease occur , patient change cohort II cohort I . Primary Outcome : Cross-sectional study ( part I ) : - What prevalence fibrotic valvular heart disease PD patient therapy ergot-derived dopamine agonists non-ergot-derived dopamine agonist ? - Is influence cumulative dose dopamine agonist ? Longitudinal study ( prospective cohort study ) : - ( Part II ) Is fibrotic valvular heart disease therapy ergot-derived dopamine agonists non-ergot-derived dopamine agonist reversible ? - ( Part III ) What ( cumulative ) incidence fibrotic valvular heart disease therapy ergot-derived dopamine agonists non-ergot-derived dopamine agonist ?</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Dopamine Agents</mesh_term>
	<mesh_term>Dopamine Agonists</mesh_term>
	<criteria>Age &gt; 18 year Diagnosis Morbus Parkinson Written inform consent Patients history carcinoid syndrome Patients history postinflammatory ( rheumatic ) , degenerative ( calcify ) ischaemic coronary heart valvular heart disease Previous medication ergotderived drug ( eg . Methysergide , Ergotamine ) except dopamine receptor agonists anorectic drug ( eg . Fenfluramine , Dexfenfluramine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>ParkinsonÂ´s disease</keyword>
	<keyword>fibrotic valvular heart fibrosis</keyword>
	<keyword>ergot dopamine agonist</keyword>
	<keyword>non-ergot dopamine agonist</keyword>
</DOC>